Sarah Carmody | Executive Director, IR and Corporate Communications |
Anna Protopapas | CEO |
Brian DeSchuytner | SVP, Finance and Product Strategy |
Jonathan Chang | SVB Leerink |
Boris Peaker | Cowen |
Debjit Chattopadhyay | H.C. Wainwright |
Jessica Fye | JP Morgan |
Mike Ulz | Baird |
David Nierengarten | Wedbush Securities |
Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year-End 2019 Conference Call. Currently, all participants are in listen-only mode. There will be a question-and-answer session at the end of this call.
I would now like to turn the call over to Sarah Carmody, Executive Director, Investor Relations and Corporate Communications. Please proceed.